Dongwha Pharm.Co.Ltd Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Dongwha Pharm.Co.Ltd.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	38.2%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Mar 26

Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

Apr 28

These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Mar 11

We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Dec 19

Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Dec 04

Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Nov 19

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Dongwha Pharm.Co.Ltd onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

KOSE:A000020 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (KRW Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	405,746	13,902	-15,571	12,915	N/A
3/31/2024	380,574	17,888	4,636	30,375	N/A
12/31/2023	361,109	27,438	2,821	29,167	N/A
9/30/2023	361,326	29,155	13,526	36,468	N/A
6/30/2023	357,324	29,177	6,752	29,906	N/A
3/31/2023	354,552	27,685	6,195	25,941	N/A
12/31/2022	340,426	20,383	9,129	29,221	N/A
9/30/2022	332,285	22,907	23,344	44,420	N/A
6/30/2022	317,901	17,410	18,460	42,210	N/A
3/31/2022	306,485	17,660	14,831	43,713	N/A
12/31/2021	293,018	17,870	11,257	36,031	N/A
9/30/2021	285,371	19,928	-15,293	33,076	N/A
6/30/2021	282,868	31,238	-9,675	33,484	N/A
3/31/2021	276,899	31,693	3,101	38,469	N/A
12/31/2020	272,075	28,508	17,582	52,228	N/A
9/30/2020	286,746	28,405	34,345	46,441	N/A
6/30/2020	294,395	16,884	38,711	44,238	N/A
3/31/2020	299,490	9,533	26,638	32,360	N/A
12/31/2019	307,150	9,116	7,779	13,285	N/A
9/30/2019	299,195	4,881	9,447	10,561	N/A
6/30/2019	299,893	5,823	-339	3,123	N/A
3/31/2019	304,302	7,202	-17,386	-14,327	N/A
12/31/2018	306,603	10,069	-8,061	-4,360	N/A
12/31/2017	258,882	47,009	N/A	-16,520	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if A000020's forecast earnings growth is above the savings rate (2.6%).

Winst versus markt: Insufficient data to determine if A000020's earnings are forecast to grow faster than the KR market

Hoge groeiwinsten: Insufficient data to determine if A000020's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if A000020's revenue is forecast to grow faster than the KR market.

Hoge groei-inkomsten: Insufficient data to determine if A000020's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if A000020's Return on Equity is forecast to be high in 3 years time

Dongwha Pharm.Co.Ltd Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

New major risk - Financial data availability

New minor risk - Profit margin trend

Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Full year 2023 earnings released: EPS: ₩991 (vs ₩736 in FY 2022)

Upcoming dividend of ₩180 per share at 1.8% yield

Full year 2022 earnings released: EPS: ₩736 (vs ₩647 in FY 2021)

Upcoming dividend of ₩180 per share

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of ₩180 per share

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS ₩197 (vs ₩82.00 in 1Q 2020)

Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

Full year 2020 earnings released: EPS ₩1,033 (vs ₩330 in FY 2019)

These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Dongwha Pharm.Co.,Ltd, Annual General Meeting, Mar 25, 2021

New 90-day low: ₩14,500

Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%

Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?

Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?

New 90-day low: ₩17,050

Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?

Investor sentiment deteriorated over the past week

Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days

Upcoming Dividend of ₩120 Per Share

Investor sentiment improved over the past week

We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Market bids up stock over the past week

Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Market pulls back on stock over the past week

Market pulls back on stock over the past week

New 90-day low: ₩20,300

Dongwha Pharm.Co.,Ltd (KOSE:A000020) agreed to acquire additional 11.18% stake in MEDYSSEY Co.,Ltd (XKON:A200580) for KRW 4 billion.

Dongwha Pharm.Co.,Ltd (KOSE:A000020) completed the acquisition of 53.3% stake in MEDYSSEY Co.,Ltd (XKON:A200580) from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim.

Dongwha Pharm.Co.,Ltd (KOSE:A000020) agreed to acquire 53.3% stake in MEDYSSEY Co.,Ltd (XKON:A200580) from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim for KRW 19.6 billion.

New 90-day high - ₩21,650

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven